First‑Line Management of Nasal Congestion and Post‑Nasal Drip in Elderly Patients

Pharmacologic First‑Line Therapy

For elderly patients with post‑nasal‑drip‑induced congestion, a combination of a first‑generation antihistamine (e.g., dexbrompheniramine 6 mg) and a decongestant (pseudoephedrine 120 mg) taken twice daily is recommended as the initial regimen because it has demonstrated efficacy in controlled studies for chronic cough secondary to post‑nasal drip【1】.
The anticholinergic activity of first‑generation antihistamines specifically reduces rhinorrhea and post‑nasal‑drip symptoms in non‑histamine‑mediated rhinitis, which is the most common form in older adults【1】.
Clinical improvement is typically observed within a few days to two weeks after starting the antihistamine/decongestant combination【1】.
Second‑generation antihistamines (e.g., loratadine, terfenadine) have been shown to be ineffective for post‑nasal‑drip‑related symptoms and should be avoided for this indication【1】.

Prior to prescribing pseudoephedrine, clinicians must confirm the absence of cerebrovascular disease, cardiac arrhythmia or angina, and hyperthyroidism in the patient【2】.
Blood pressure should be monitored during therapy because pseudoephedrine can cause a modest rise in systolic/diastolic pressure, as well as insomnia, irritability, and palpitations【2】.

If the first‑generation antihistamine/decongestant regimen is contraindicated (e.g., due to glaucoma or prostatic hypertrophy) or fails to control symptoms, intranasal ipratropium bromide spray should be added; it is especially effective for rhinorrhea and is associated with minimal side effects, although nasal dryness may occur【1】【2】.
Combining intranasal ipratropium with an intranasal corticosteroid provides superior control of rhinorrhea compared with either agent alone, without increasing adverse events【2】.

In patients where pseudoephedrine is unsuitable because of cardiovascular contraindications, the initial approach should be an intranasal corticosteroid (e.g., fluticasone, mometasone, or budesonide) together with ipratropium bromide nasal spray to address both congestion and rhinorrhea【2】.
Nasal saline irrigation can be used as an adjunctive measure, offering modest benefit for chronic rhinorrhea【2】.

Using a first‑generation antihistamine without a decongestant in older adults can lead to significant sedation, cognitive impairment, and anticholinergic effects such as urinary retention, confusion, and increased fall risk【2】.
Patients should be counseled about these potential adverse effects, with particular emphasis on sedation and anticholinergic symptoms【2】.

The American Academy of Allergy, Asthma, and Immunology recommends starting with oral pseudoephedrine alone and reserving intranasal oxymetazoline for second-line use due to the high risk of rhinitis medicamentosa 3, 4

Topical decongestants like oxymetazoline are not recommended for continuous use beyond 3-5 days due to the risk of rhinitis medicamentosa, nasal hyperreactivity, and mucosal damage 3, 4
The American Academy of Otolaryngology-Head and Neck Surgery states that topical decongestants can create a vicious cycle of dependency and worsening congestion 4

Pseudoephedrine effectively reduces nasal congestion in both allergic and nonallergic rhinitis without the risk of rhinitis medicamentosa 3, 5, 6
The American College of Allergy, Asthma, and Immunology notes that pseudoephedrine has a mild side effect profile, including insomnia, irritability, and modest blood pressure elevation 3, 4

Start with oral pseudoephedrine 60mg every 4-6 hours as needed, and consider adding an intranasal corticosteroid if inadequate response after 2-3 days 3, 5, 6
The American Academy of Allergy, Asthma, and Immunology recommends reserving oxymetazoline for severe refractory cases with explicit patient counseling, limiting use to maximum 3-5 consecutive days only 3, 4

Monitor and use caution with pseudoephedrine in patients with uncontrolled hypertension, cardiovascular disease, cerebrovascular disease, hyperthyroidism, closed-angle glaucoma, bladder neck obstruction, or concurrent use of CNS stimulants 3, 4, 7
Avoid pseudoephedrine in children under 6 years due to the risk of serious adverse events 3

Never prescribe Afrin for routine daily use due to the risk of rhinitis medicamentosa 3, 4
Don't assume all patients need combination therapy upfront, and start with pseudoephedrine monotherapy 3
Don't forget to monitor blood pressure in patients with hypertension taking pseudoephedrine 3, 4